Remove Packaging Remove Pharma Companies Remove Pharmaceutical Companies Remove Trials
article thumbnail

Scandinavia: insight into opportunities for drug discovery

Drug Discovery World

Magnus Persson is a physician and scientist with a background in both academia and industry, working for the likes of Sanofi on clinical trials activities and across venture capital firms in the US. He is now a founding partner of EIR Ventures, a venture capital firm investing in innovative companies across the Nordics. “We

Science 130
article thumbnail

Q&A: The IND Journey Phase I – Navigating Success

Advarra

The sponsor is the pharmaceutical company conducting the trial. If you mean using a different contract research organization (CRO) for the different phases of clinical trials – that’s different. Also consider CRO oversight, trial management, data handling and record keeping, as well as allocation of responsibilities.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Case study: Extracting tidy data from Open Targets Genetics with Otargen

The Open Targets Blog

Amir has worked in the pharma/biotech sector for over ten years, using bioinformatics for data integration and multi-omics analysis for target identification and validation, and his team were an early adopter of Open Targets Genetics.  This is where our idea for an R package came from. 

article thumbnail

What it takes to make cancer research more inclusive

Drug Discovery World

These observations may come to light in the clinic, but these disparities can be attributed to every phase of the drug development pipeline – clinical trials, translational research and, ultimately, drug discovery. . Additionally, the lack of diversity in patients participating in clinical trials can also contribute to cancer disparities.

Research 130
article thumbnail

Scaling Phage Therapy

Codon

1 Yet even after more than two decades of research, media hype, and dozens of clinical trials and biotech start-ups that have come and gone, phage therapy has not scaled. No phage-based therapeutic has reached the latter stages of the clinical trial pipeline (where promising results lead to an expanded trial involving thousands of patients).

Therapies 118